As the pharmacist pipeline tightens, leaders from UC Davis Health, UCSF Health, and Sutter Health say financial sustainability now depends as much on capacity as on cost.
|Articles|January 1, 2004
New medications for rheumatoid arthritis are effective but expensive
Author(s)Elaine Zablocki
First line treatment usualy begins with NSAIDs plus a DMARD, but combination therapy and new biologics hold great promise
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
GLP-1 therapy tied to lower mortality and liver decompensation in older adults with MASLD
2
Kaiser’s formulary chief makes his case for a ‘total value’ model on biologics | HSES 2026
3
Health-system pharmacy leaders are being asked to solve a margin problem and it is costing hospitals | HSES 2026
4
The GLP-1 access gap in type 2 diabetes isn’t coverage — it’s physician awareness | HSES 2026
5